Akriti Jain
YOU?
Author Swipe
View article: Is there a best frontline therapy in chronic myeloid leukemia?
Is there a best frontline therapy in chronic myeloid leukemia? Open
The management of chronic myeloid leukemia in chronic phase (CML-CP) was transfigured with the introduction of imatinib in 2001. Since then, four other tyrosine kinase inhibitors (TKIs), dasatinib, nilotinib, bosutinib and most recently as…
View article: Spliceosome mutations in AML: Prevalence, clinical features, and treatment outcomes in a contemporary cohort
Spliceosome mutations in AML: Prevalence, clinical features, and treatment outcomes in a contemporary cohort Open
Background Spliceosomes are intranuclear proteins that splice pre-mRNA into mature mRNA. Somatic mutations in genes encoding spliceosome components are found in acute myeloid leukemia (AML) and can occur in SRSF2, U2AF1, SF3B1, ZRSR2, and,…
View article: Comparative risk of major adverse cardiovascular events in polycythemia vera patients treated with ruxolitinib, hydroxyurea, or interferon: A real-world, propensity-matched cohort study
Comparative risk of major adverse cardiovascular events in polycythemia vera patients treated with ruxolitinib, hydroxyurea, or interferon: A real-world, propensity-matched cohort study Open
Background: Vascular complications are the primary cause of morbidity and mortality in patients with polycythemia vera (PV), yet consensus is lacking on the optimal cytoreductive therapy to reduce risk. Hydroxyurea (HU) is used commonly, t…
View article: Trial in progress: Pilot trial of olutasidenib maintenance post allogeneic hematopoietic cell transplantation in patients carrying IDH1 mutation with AML, MDS, or CMML
Trial in progress: Pilot trial of olutasidenib maintenance post allogeneic hematopoietic cell transplantation in patients carrying IDH1 mutation with AML, MDS, or CMML Open
Study Rationale. Relapse remains a major cause of treatment failure following allogeneic hematopoietic cell transplantation (alloHCT) in patients with acute myeloid leukemia (AML), with rates approaching 40%. Mutations in IDH1 are prevalen…
View article: Survival and risk of second primary malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors: A retrospective US population-level analysis
Survival and risk of second primary malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors: A retrospective US population-level analysis Open
INTRODUCTION The introduction of tyrosine kinase inhibitors (TKIs) has significantly increased the survival of patients (pts) with chronic myeloid leukemia (CML). With a growing population of long-term CML survivors, there are now question…
View article: Management and outcomes of patients diagnosed with chronic myeloid leukemia in blast Phase: A multicenter analysis by the h jean khoury cure CML consortium
Management and outcomes of patients diagnosed with chronic myeloid leukemia in blast Phase: A multicenter analysis by the h jean khoury cure CML consortium Open
Introduction: Despite advent of multiple tyrosine kinase inhibitors (TKIs) and newer treatment methods for AML and ALL, the outcomes of patients (pts) with chronic myeloid leukemia in blast phase (CML-BP) remain poor. Consensus guidelines …
View article: Risk of second primary malignancies and leukemic transformation in patients with Philadelphia chromosome-negative myeloproliferative neoplasms: A population-level US retrospective cohort study
Risk of second primary malignancies and leukemic transformation in patients with Philadelphia chromosome-negative myeloproliferative neoplasms: A population-level US retrospective cohort study Open
INTRODUCTION There is sparse population-level data on the risk of second primary malignancy (SPM) and leukemic transformation in Philadelphia chromosome-negative myeloproliferative neoplasms (Ph-MPNs) patients (pts) in the US. In this retr…
View article: Major adverse cardiovascular events (MACE) in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A target trial emulation study
Major adverse cardiovascular events (MACE) in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A target trial emulation study Open
Background: Since tyrosine kinase inhibitors (TKIs) have transformed chronic myeloid leukemia (CML) into a chronic disease with near-normal life expectancy, cardiovascular toxicity has emerged as a leading cause of non-CML mortality. Yet, …
View article: Combining drugs that bypass p53 to treat TP53-mutated leukemias
Combining drugs that bypass p53 to treat TP53-mutated leukemias Open
Acute myeloid leukemias (AMLs) containing TP53 (p53) mutations are routinely treated with decitabine or 5-azacytidine which deplete DNA methyltransferase 1 (DNMT1)('hypomethylating agents', HMA). Unfortunately, resistance/relapse, characte…
View article: Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (≥ 70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia
Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (≥ 70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia Open
View article: Disparities in real-world treatment patterns of hypomethylating agents among patients with MDS in the United States
Disparities in real-world treatment patterns of hypomethylating agents among patients with MDS in the United States Open
View article: Impact of Cytogenetic Response to Therapy on Long‐Term Survival in Acute Myeloid Leukemia
Impact of Cytogenetic Response to Therapy on Long‐Term Survival in Acute Myeloid Leukemia Open
Prognostication in acute myeloid leukemia (AML) relies on clinical, molecular, and cytogenetic factors. In this retrospective study, we examined the impact of different levels of cytogenetic response on overall survival (OS) and event‐free…
View article: A comparative assessment of molecular-based prognostic models in CMML
A comparative assessment of molecular-based prognostic models in CMML Open
View article: Comparing Outcomes of First-Line Intensive Chemotherapeutic Regimens in Adult Patients with Acute Lymphoblastic Leukemia at a Tertiary Center
Comparing Outcomes of First-Line Intensive Chemotherapeutic Regimens in Adult Patients with Acute Lymphoblastic Leukemia at a Tertiary Center Open
View article: Care Models for Cancer Survivors
Care Models for Cancer Survivors Open
The population of cancer survivors is on the rise due to an increase in cancer incidence and a decline in cancer mortality. This growing survivor population creates a number of challenges. Although there have been improvements in care plan…
View article: Distinct clinico-genomic factors drive outcomes in patients with myelofibrosis and disease-related anemia
Distinct clinico-genomic factors drive outcomes in patients with myelofibrosis and disease-related anemia Open
Background Disease related anemia in myelofibrosis (MF) is common and prognostically detrimental. Anemia in MF poses a therapeutic challenge as it contributes to poor quality of life and often interferes with JAK inhibitor therapy. Still, …
View article: Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes Open
View article: Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia
Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia Open
Introduction: We aimed to compare outcomes of patients with AML treated with frontline hypomethylating agent and venetoclax (HMA + Ven) who achieved complete remission (CR), complete remission with partial hematologic recovery (CRh), compl…
View article: Association between myeloid disorders and adult onset-inflammatory syndromes, successful treatment with JAK-inhibitors: Case series and literature review
Association between myeloid disorders and adult onset-inflammatory syndromes, successful treatment with JAK-inhibitors: Case series and literature review Open
Approximately one-third of patients with myeloid disorders like myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) exhibit inflammatory and autoimmune disorders (IADs). These IADs often include atypical and incomplet…
View article: Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML
Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML Open
Dasatinib is one of the second generation tyrosine kinase inhibitors (TKI) which is approved for the treatment of patients with chronic phase CML (CP-CML) both in the front line and in the second line setting. Pleural effusion (PE) is a un…
View article: Outcomes by Best Response With Hypomethylating Agent Plus Venetoclax in Adults with Previously Untreated Acute Myeloid Leukemia
Outcomes by Best Response With Hypomethylating Agent Plus Venetoclax in Adults with Previously Untreated Acute Myeloid Leukemia Open
Introduction: We aimed to compare outcomes of patients with AML treated with frontline hypomethylating agent and venetoclax (HMA+Ven) who achieved complete remission (CR), complete remission with partial hematologic recovery (CRh), complet…
View article: Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia
Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia Open
The patterns of low risk myelodysplastic syndrome (MDS) progression, and the clinical and molecular features of those patterns are not well described. We divided our low risk (LR) MDS patients (n=1914) into 4 cohorts: 1) Patients who remai…
View article: Drivers of deep molecular response and long‐term outcomes in patients with core binding factor acute myeloid leukemia
Drivers of deep molecular response and long‐term outcomes in patients with core binding factor acute myeloid leukemia Open
A swimmer plot on clinical course of patients undergoing allogeneic stem cell transplant for core binding factor acute myeloid leukemia.
View article: P727: REFINING RISK STRATIFICATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): A COMPREHENSIVE ASSESSMENT OF THE IPSS-M AND OTHER MOLECULARLY INTEGRATED PROGNOSTIC MODELS
P727: REFINING RISK STRATIFICATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): A COMPREHENSIVE ASSESSMENT OF THE IPSS-M AND OTHER MOLECULARLY INTEGRATED PROGNOSTIC MODELS Open
Background: CMML is a hematopoietic disorder of clonal ontogeny associated with poor outcomes. Multiple molecularly informed models have been designed in hopes of improving prognostication. More recently, the IPSS-M risk model for MDS has …
View article: S170: MYELODYSPLASTIC NEOPLASMS (MDS) CLASSIFICATION FROM WHO 2017 TO WHO 2022 AND ICC 2022): AN EXPANDED ANALYSIS OF 7017 PATIENTS ON BEHALF OF THE INTERNATIONAL CONSORTIUM FOR MDS (ICMDS)
S170: MYELODYSPLASTIC NEOPLASMS (MDS) CLASSIFICATION FROM WHO 2017 TO WHO 2022 AND ICC 2022): AN EXPANDED ANALYSIS OF 7017 PATIENTS ON BEHALF OF THE INTERNATIONAL CONSORTIUM FOR MDS (ICMDS) Open
Topic: 10. Myelodysplastic syndromes - Clinical Background: In 2022 two new classifications for myeloid neoplasms were published: the World Health Organization (WHO) and International Consensus Classification (ICC). Aims: To validate and c…
View article: Utilization of Serial Next-Generation Sequencing Among Patients Receiving CPX-351 for Newly Diagnosed Acute Myeloid Leukemia
Utilization of Serial Next-Generation Sequencing Among Patients Receiving CPX-351 for Newly Diagnosed Acute Myeloid Leukemia Open
View article: Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients
Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients Open
Background Compared to the general population, cancer patients are at higher risk of morbidity and mortality following SARS‐CoV‐2 infection. The immune response to a two‐dose regimen of mRNA vaccines in cancer patients is generally lower t…
View article: Blastic Plasmacytoid Dendritic Cell Neoplasm
Blastic Plasmacytoid Dendritic Cell Neoplasm Open
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with an aggressive clinical course and poor prognosis. BPDCN is most often characterized by its presentation with distinct cutaneous lesions. Bone marrow…
View article: Table of Contents
Table of Contents Open
View article: Real-world experience with CPX-351 in high-risk acute myeloid leukemia
Real-world experience with CPX-351 in high-risk acute myeloid leukemia Open